TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10445104

Group type: COMPARATOR
Intervention: Gonadotropins (GN) alone for 6 months
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Gonadotropins (GN) combined with growth hormone (GH) for 6 months
Number of subjects: 4
Study: 2142930

Group type: EXPERIMENTAL
Intervention: Gestodene-containing formulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Desogestrel-containing formulation
Number of subjects: 18
Study: 902005

Group type: EXPERIMENTAL
Intervention: Counselling on medication errors
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tear-off daily calendar
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Pill wheel
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Tablet identification card
Number of subjects: 165
Study: 30862265

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) for transferred patients
Number of subjects: 1526
Study: 28505332

Group type: EXPERIMENTAL
Intervention: DMF-exposed workers
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Male DMF-exposed workers
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: NMF
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: AMCC
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: NMHb
Number of subjects: 886
Study: 26458813

Group type: EXPERIMENTAL
Intervention: Titanium-zirconium (TiZr) implants
Number of subjects: 47

Group type: COMPARATOR
Intervention: Titanium Grade IV (Ti Grade IV) implants
Number of subjects: 47
Study: 23992793

Group type: EXPERIMENTAL
Intervention: General therapy skills (feedback and understanding)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Technical skill of guided discovery
Number of subjects: 79
Study: 21574351

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted therapy (V.A.C. Therapy system)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard therapy (including debridement)
Number of subjects: 43
Study: 19121493

Group type: EXPERIMENTAL
Intervention: Sandblasting on the base of brackets (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sandblasting + silane-coupling agent (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tribochemical treatment (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reconditioned with sandblasting (Group 5)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group 4)
Number of subjects: 80
Study: 16713778

Group type: COMPARATOR
Intervention: Midazolam (7 mg)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Etomidate (20 mg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Benzodiazepine for failed etomidate intubation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Benzodiazepine for failed midazolam intubation
Number of subjects: 110
Study: 15514879

Group type: EXPERIMENTAL
Intervention: Lateral Condensation (LC)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hybrid Condensation (HC)
Number of subjects: 79
Study: 11312014

Group type: EXPERIMENTAL
Intervention: Monovalent dengue vaccines (dengue-1, dengue-2, dengue-3, dengue-4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vaccine vehicle (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All dengue-3, dengue-4, and tetravalent vaccine recipients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue-1 and dengue-2 vaccine recipients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dengue-2, dengue-3, dengue-4, and 60% of dengue-1 vaccine recipients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine recipients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Seven volunteers
Number of subjects: 40
Study: 9250115

Group type: EXPERIMENTAL
Intervention: Oat-bran test meal (16.3 g fiber)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Wheat test meal (6.3 g fiber)
Number of subjects: 6
Study: 7945494

Group type: EXPERIMENTAL
Intervention: Corticosteroids (0.5 mg/kg of prednisone daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3652280

Group type: EXPERIMENTAL
Intervention: Azlocillin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azlocillin plus amikacin
Number of subjects: 0
Study: 31972396

Group type: EXPERIMENTAL
Intervention: Protein biomarker signature for early detection of CRC derived from 270 protein markers measured in plasma samples.
Number of subjects: 100

Group type: COMPARATOR
Intervention: External validation of the protein biomarker signature in a representative screening population.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three-marker early-stage algorithm for detection of AA.
Number of subjects: 100
Study: 30061275

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 60
Study: 27181755

Group type: EXPERIMENTAL
Intervention: Standard Diabetes Manual + Diabetes Treatment Guide + 30-min seminar
Number of subjects: 416

Group type: COMPARATOR
Intervention: Diabetes Treatment Guide only
Number of subjects: 416
Study: 25916420

Group type: EXPERIMENTAL
Intervention: Audible music group (MG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mute music group (CG)
Number of subjects: 33
Study: 22246660

Group type: EXPERIMENTAL
Intervention: Automated multi-behavior intervention
Number of subjects: 337

Group type: COMPARATOR
Intervention: Education-only control
Number of subjects: 337
Study: 20537615

Group type: EXPERIMENTAL
Intervention: Oral naltrexone (50 mg daily)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Implant naltrexone (2.3 g single dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Blood naltrexone concentration < 0.5 ng/mL
Number of subjects: 69

Group type: COMPARATOR
Intervention: Blood naltrexone concentration 3 ng/mL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Implant naltrexone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral naltrexone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Lower craving scores (<= 20/70)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Noncompliance with daily oral formula, higher baseline craving, longer history of use, being younger
Number of subjects: 69
Study: 18672743

Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture (n = 23), administered once daily for the first three days and once every three days for the remaining 11 days, plus placebo pill once daily
Number of subjects: 44
Study: 15939389

Group type: EXPERIMENTAL
Intervention: Trabeculectomy surgery
Number of subjects: 300
Study: 12617044

Group type: EXPERIMENTAL
Intervention: Laparoscopic operation using the overlap technique and intraperitoneal mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open technique with overlap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesh repair for larger hernias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tension-free technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overlap technique
Number of subjects: 0
Study: 10352763

Group type: EXPERIMENTAL
Intervention: Biceps load test
Number of subjects: 75
Study: 7482644

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 34)
Number of subjects: 71

Group type: COMPARATOR
Intervention: General wards (n = 37)
Number of subjects: 71
Study: 1781820

Group type: EXPERIMENTAL
Intervention: Prednisone 1.5 mg/kg/d
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study: 121456

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 17
Study: 31960773

Group type: EXPERIMENTAL
Intervention: Deep dry needling with needle manipulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Deep dry needling without needle manipulation
Number of subjects: 42
Study: 30877596

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Support group
Number of subjects: 63
Study: 28129492

Group type: EXPERIMENTAL
Intervention: Topiramate (25-200 mg/d for 12 weeks)
Number of subjects: 10
Study: 26239090

Group type: EXPERIMENTAL
Intervention: High-dose UFH (100 U/kg bolus followed by age-based continuous infusion)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Low-dose UFH (50 U/kg bolus)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: UFH dose and effect
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Anti-Xa, aPTT, ACT assays
Number of subjects: 149
Study: 23390076

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 21081593

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV) delivered with a T‐piece or self‐inflating bag and a round silicone face mask.
Number of subjects: 56
Study: 19329177

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 15548

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15548
Study: 16311083

Group type: EXPERIMENTAL
Intervention: Combined administration of octreotide and methylglucamine diatrizoate
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (treated conservatively)
Number of subjects: 162
Study: 15344622

Group type: EXPERIMENTAL
Intervention: Gray MTA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White MTA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 24
Study: 11757832

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin + rifampicin (50 mg/L each)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cephradine (250 mg/L)
Number of subjects: 98
Study: 9048273

Group type: EXPERIMENTAL
Intervention: Fantofarone 100 mg twice daily
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Fantofarone 150 mg twice daily
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Fantofarone (100-150 mg twice daily)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Fantofarone (all doses)
Number of subjects: 330
Study: 8151104

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 g of OA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 g of OA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 g of OA
Number of subjects: 10
Study: 3529043

Group type: EXPERIMENTAL
Intervention: Cotton/polyester covergowns worn over scrubsuits during lunch period outside the OR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh scrubsuits put on following the lunch period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scrubsuits worn unprotected outside the OR during lunch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scrubsuits removed before and put on again following lunch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental treatments affecting incidence of S. aureus contamination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wearing covergowns
Number of subjects: 0
Study: 29237131

Group type: EXPERIMENTAL
Intervention: 12% SDF applied annually
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 12% SDF applied semiannually
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 38% SDF applied annually
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 38% SDF applied semiannually
Number of subjects: 888
Study: 27347302

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 1µg/kg of clonidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with placebo
Number of subjects: 40
Study: 24556040

Group type: EXPERIMENTAL
Intervention: Dovitinib (500 mg orally, 5 days on and 2 days off)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Dovitinib
Number of subjects: 570

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 570
Study: 23174050

Group type: EXPERIMENTAL
Intervention: 3% SIG1273 gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 30
Study: 20923901

Group type: EXPERIMENTAL
Intervention: Parenting interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Services as usual (control group)
Number of subjects: 0
Study: 16430546

Group type: COMPARATOR
Intervention: Bupivacaine (12 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine (12 mg) + Dexmedetomidine (3 microg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine (12 mg) + Clonidine (30 microg)
Number of subjects: 60
Study: 11573379

Group type: EXPERIMENTAL
Intervention: Rescreening for AAA at five-year intervals for men with initially ectatic aortas sized 25-29 mm
Number of subjects: 6339

Group type: EXPERIMENTAL
Intervention: Observation of small AAA
Number of subjects: 6339

Group type: COMPARATOR
Intervention: Control group of men (380 men)
Number of subjects: 6339

Group type: EXPERIMENTAL
Intervention: Men with a ratio > 1.2
Number of subjects: 6339
Study: 9254267

Group type: EXPERIMENTAL
Intervention: Magnetothermia combined with chemotherapy using fluorouracil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Monotherapy with fluorouracil
Number of subjects: 11
Study: 8494129

Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 30
Study: 2892130

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus a long course (nine days) of amikacin
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus a short course (three days) of amikacin
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Azlocillin plus a long course (nine days) of amikacin
Number of subjects: 872
Study: 30606384

Group type: EXPERIMENTAL
Intervention: Attending the 'Red Ribbon in Colleges' event
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Receiving AIDS prevention education as a freshman
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Filling in AIDS prevention questionnaires
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Attending other AIDS-related health education events in schools or colleges
Number of subjects: 1977

Group type: COMPARATOR
Intervention: Not attending any of these events
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Majoring in engineering disciplines
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Being a junior student
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Living in central China
Number of subjects: 1977

Group type: EXPERIMENTAL
Intervention: Living in northern China
Number of subjects: 1977
Study: 26643687

Group type: EXPERIMENTAL
Intervention: Educational program (G-I, n = 137)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (G-II, n = 119)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both groups underwent the educational program at T-12
Number of subjects: 256
Study: 24952836

Group type: EXPERIMENTAL
Intervention: Kinesio Taping with skin convolutions (10 to 15% tension applied in flexion)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Kinesio Taping with no tension (sham taping)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Kinesio Taping with skin convolutions
Number of subjects: 148
Study: 22969230

Group type: EXPERIMENTAL
Intervention: Composite yogurt enriched with acacia dietary fiber and Bifidobacterium lactis (B. lactis), consumed twice daily for 8 weeks
Number of subjects: 130
Study: 20356870

Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 19027263

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg bolus followed by 0.25 mg/kg per hour continuous infusion)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0.5 mg/kg bolus followed by 0.25 mg/kg per hour continuous infusion)
Number of subjects: 36
Study: 16122472

Group type: EXPERIMENTAL
Intervention: Patients after arch repair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Age-matched control subjects
Number of subjects: 20
Study: 12735675

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg b.d. plus FP250 (SM/FP250)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Fluticasone propionate 250 microg b.d. (FP250)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Fluticasone propionate 500 microg b.d. (FP500)
Number of subjects: 496
Study: 11158748

Group type: EXPERIMENTAL
Intervention: Intrarectal artesunate (10 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intrarectal artesunate (20 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous artesunate (2.4 mg/kg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 34
Study: 9266868

Group type: EXPERIMENTAL
Intervention: Albuterol every 30 min (group 1, n=34)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albuterol every 60 min (group 2, n=33)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Albuterol every 120 min (group 3, n=33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albuterol treatment for low responders (<15 percentage point increase at 15 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albuterol treatment for high responders (>15 percentage point increase at 15 min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Potassium levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adverse events and hospitalization rates
Number of subjects: 100
Study: 8499939

Group type: EXPERIMENTAL
Intervention: Liquid meal feeding (MW)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Liquid meal feeding (M)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (W)
Number of subjects: 10
Study: 3810772

Group type: EXPERIMENTAL
Intervention: Medical therapy (high normal hemoglobin concentration, 15 g/l or more)
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Medical therapy (lower hemoglobin concentration, less than 15 g/l)
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: Surgical therapy (extracranial‐intracranial bypass)
Number of subjects: 1377
Study: 30138152

Group type: EXPERIMENTAL
Intervention: High-intensity educational intervention (n = 100)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low-intensity educational intervention (n = 101)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: High-intensity educational intervention
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Self-sampling
Number of subjects: 201
Study: 27687417

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate 20 mg/kg in bolus followed by magnesium 2 mg kg(‐1) h(‐1) (group M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg in bolus followed by saline infusion (group K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous saline solution 20 mL in bolus followed by saline infusion during the entire procedure (group S)
Number of subjects: 60
Study: 25626413

Group type: EXPERIMENTAL
Intervention: High-calcium milk powder supplementation (50g containing 450mg elemental calcium and 400IU vitamin D, taken every morning and evening)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High-calcium milk powder supplementation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 141
Study: 24320907

Group type: EXPERIMENTAL
Intervention: L-arginine dietary supplement (3g)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 21403011

Group type: EXPERIMENTAL
Intervention: Bupropion slow-release (SR)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 18600319

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET
Number of subjects: 160

Group type: COMPARATOR
Intervention: MDCT
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Side‐by‐side visual correlation of MDCT and (18)F‐FDG PET
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: (18)F‐FDG PET and extended‐field MDCT
Number of subjects: 160
Study: 17194262

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 80
Study: 12727949

Group type: EXPERIMENTAL
Intervention: 3 mg continuous estradiol with 10 mg medroxyprogesterone acetate
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2 mg continuous estradiol with 10 mg medroxyprogesterone acetate
Number of subjects: 28
Study: 10802791

Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy (QOLIE)-89
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of Life in Epilepsy (QOLIE)-31
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short Form (SF)-36, IRT scoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short Form (SF)-36, classic test theory scoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short Form (SF)-12
Number of subjects: 0
Study: 8751806

Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Granisetron plus methylprednisolone (MPL)
Number of subjects: 12
Study: 1478583

Group type: EXPERIMENTAL
Intervention: Transfer of the posterior tibialis tendon (N = 9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lengthening of the posterior tibialis tendon (N = 6)
Number of subjects: 15
Study: 6397328

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 200 mg injection every 60 +/‐ 5 days
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 200 mg injection every 90 +/‐ 5 days
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Norethisterone oenanthate (NET OEN) 200 mg injection
Number of subjects: 2388
Study: 31196166

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal pancreatectomy (LDP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open distal pancreatectomy (ODP)
Number of subjects: 60
Study: 28733270

Group type: EXPERIMENTAL
Intervention: Web-based coaching program using EHRs
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine care with the addition of the Web-based coaching program using EHRs
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 130